2.19
price up icon6.31%   0.13
after-market Dopo l'orario di chiusura: 2.14 -0.05 -2.28%
loading

Immix Biopharma Inc Borsa (IMMX) Ultime notizie

pulisher
04:10 AM

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - Insider Monkey

04:10 AM
pulisher
03:06 AM

Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright - Defense World

03:06 AM
pulisher
Jun 04, 2025

Immix Biopharma (IMMX) Achieves Significant Clinical Milestone w - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | IMMX Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma Announces Primary Endpoint Met in positive - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma reports high response rate in AL Amyloidosis trial By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma stock soars to 52-week high of $2.99 By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

immix biopharma enters at-the-market offering agreement By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma stock soars to 52-week high of $2.99 - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma Enters At The Market Offering Agreement - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

immix biopharma enters at-the-market offering agreement - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025 - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ... - Eagle-Tribune

Jun 03, 2025
pulisher
May 29, 2025

Immix Biopharma — Positive newsflow continues for NEXICART-2 - Smartkarma

May 29, 2025
pulisher
May 23, 2025

Immix Biopharma accelerates NEXICART-2 trial enrollment By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Sto - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com India

May 23, 2025
pulisher
May 22, 2025

Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune

May 22, 2025
pulisher
May 21, 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis - The Manila Times

May 21, 2025
pulisher
May 21, 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire

May 21, 2025
pulisher
May 19, 2025

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Immix Biopharma — Steady progress in Q125 - Smartkarma

May 19, 2025
pulisher
May 05, 2025

Immix Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 01, 2025

Immix Biopharma (IMMX) to Release Earnings on Thursday - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - simplywall.st

Apr 30, 2025
pulisher
Apr 23, 2025

Immix Biopharma Announces Oral Presentation of NXC-201 Phase 1/2 Trial Data at ASCO 2025 - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Groundbreaking CAR-T Therapy for AL Amyloidosis: First US Trial Data Earns Prestigious ASCO Spotlight - Stock Titan

Apr 23, 2025
pulisher
Apr 03, 2025

Immix Biopharma — All eyes on NEXICART-2 - Smartkarma

Apr 03, 2025
pulisher
Mar 28, 2025

Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 25, 2025

Immix Biopharma Inc. (IMMX) reports earnings - Quartz

Mar 25, 2025
pulisher
Mar 20, 2025

Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 13, 2025

Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma

Mar 13, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Mar 12, 2025
pulisher
Mar 04, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World

Mar 04, 2025
pulisher
Feb 13, 2025

HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis - OncLive

Feb 13, 2025
pulisher
Feb 12, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 11, 2025
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Capitalizzazione:     |  Volume (24 ore):